Amiloride

Generic Name: Amiloride

Brand Names: Midamor

Drug Type: Small Molecule

Chemical Formula: C_₆H_₈ClN_₇O

CAS Number: 2609-46-3

Unique Ingredient Identifier: 7DZO8EB0Z3

Background: A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)

Indication: For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.

Associated Conditions: Ascites, Calcium Nephrolithiasis, Congestive Heart Failure (CHF), Hypertension, Hypokalemia, Metabolic Alkalosis, Polyuria

Associated Therapies: -

Clinical Trials

Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes

Early Phase 1

Terminated

Conditions: Proteinuria
Hypertension
Type II Diabetes

Interventions: Drug: Amiloride
Drug: HCTZ

First Posted Date: 2013-03-05

Last Posted Date: 2018-05-11

Lead Sponsor: University of New Mexico

Target Recruit Count: 9

Registration Number: NCT01804777

Locations: 🇺🇸
University of New Mexico Hospital; Clinical & Translational Science Center, Albuquerque, New Mexico, United States

Amiloride Clinical Trial In Optic Neuritis

Phase 2

Completed

Conditions: Optic Neuritis
Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Amiloride

First Posted Date: 2013-03-01

Last Posted Date: 2018-05-17

Lead Sponsor: University of Oxford

Target Recruit Count: 46

Registration Number: NCT01802489

Locations: 🇬🇧
John Radcliffe Hospital, Oxford, United Kingdom

Amiloride Hydrochloride as an Effective Treatment for ADHD

Early Phase 1

Terminated

Conditions: ADHD

Interventions: Drug: amiloride
Behavioral: Behavioral

First Posted Date: 2012-11-27

Last Posted Date: 2018-07-20

Lead Sponsor: State University of New York - Upstate Medical University

Target Recruit Count: 3

Registration Number: NCT01733680

Locations: 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States

The Effect of Amiloride and Spironolactone in Patients With Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Spironolactone
Drug: Amiloride
Drug: Placebo

First Posted Date: 2011-07-06

Last Posted Date: 2012-03-28

Lead Sponsor: Erling Bjerregaard Pedersen

Target Recruit Count: 23

Registration Number: NCT01388088

Locations: 🇩🇰
Department of Medical Research, Holstebro, Denmark

Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension

Phase 4

Conditions: Prehypertension

Interventions: Drug: Amiloride

First Posted Date: 2011-03-04

Last Posted Date: 2012-10-23

Lead Sponsor: Augusta University

Target Recruit Count: 32

Registration Number: NCT01308983

Locations: 🇺🇸
Georgia Prevention Institute, Augusta, Georgia, United States

Microcirculation & ASICs

Not Applicable

Completed

Conditions: Physiological Conditions

First Posted Date: 2010-11-23

Last Posted Date: 2019-05-28

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 20

Registration Number: NCT01246180

Locations: 🇫🇷
Pôle d'activité medicale-Centre Hospitalier Lyon Sud-Hospices Civils de Lyon, Pierre Bénite, France

Treatment of Coronary Heart Disease With Amiloride

Phase 2

Completed

Conditions: Coronary Heart Disease

Interventions: Drug: Nitrates, clopidogrel, aspirin, statins
Drug: Amiloride

First Posted Date: 2010-11-01

Last Posted Date: 2012-06-11

Lead Sponsor: University of Carabobo

Target Recruit Count: 70

Registration Number: NCT01231165

Locations: 🇻🇪
Hypertension Research Unit, Valencia, Carabobo, Venezuela

Novel Treatment for Coronary Artery Disease

Phase 2

Conditions: Coronary Artery Disease

Interventions: Drug: amiloride
Drug: Placebo

First Posted Date: 2010-10-26

Last Posted Date: 2013-03-19

Lead Sponsor: University of Carabobo

Target Recruit Count: 100

Registration Number: NCT01228214

Locations: 🇻🇪
Hypertension Research Unit, Valencia, Carabobo, Venezuela

The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables

Not Applicable

Completed

Conditions: Essential Hypertension

Interventions: Other: Placebo
Drug: Spironolactone
Drug: Amiloride

First Posted Date: 2010-09-06

Last Posted Date: 2015-08-20

Lead Sponsor: Regional Hospital Holstebro

Target Recruit Count: 25

Registration Number: NCT01195805

Locations: 🇩🇰
Departments of medical research and medicine, Holstebro, Denmark

Do Acid Sensing Ion Channels Contribute to Heartburn?

Phase 1

Completed

Conditions: Gastroesophageal Reflux Disease
Heartburn

Interventions: Drug: Amiloride
Drug: Placebo

First Posted Date: 2010-03-30

Last Posted Date: 2012-09-20

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 24

Registration Number: NCT01095133

Locations: 🇺🇸
The Clinical and Translational Research Center, Chapel Hill, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy